Schematy EQA

To assess the proficiency of laboratories in detection and quantitation of B19 virus.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To evaluate the ability of laboratories in the molecular detection of hepatitis A virus (HAV) in terms of sensitivity and specificity.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection and quantitation of hepatitis B virus (HBV).

To assess the proficiency of laboratories is the detection and quantitation of different HBV genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the correct genotyping of hepatitis B virus (HBV) using molecular methods.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the correct genotyping of hepatitis C virus (HCV) using molecular methods.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection and quantitation of hepatitis C virus (HCV) RNA.

To assess the proficiency of laboratories in the detection and quantitation of different HCV genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of human immunodeficiency virus type 1(HIV-1) pro-viral DNA.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in detection and quantitation of human immunodeficiency virus (HIV) RNA.

To assess the proficiency of laboratories in detection and quantitation of different HIV genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess proficiency of laboratories in the detection of Chlamydia trachomatis and Neisseria gonorrhoeae using molecular technologies.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the ability of laboratories molecular assays to detect different types and concentrations of enterovirus (EV).

To review the performance of laboratories quantitative EV molecular assays.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess laboratories ability to correctly identify specific enterovirus types using their routine molecular method and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the ability of laboratories molecular assays to detect different types and concentrations of herpes simplex virus (HSV).

To review the performance of laboratories quantitative HSV molecular assays.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of drug resistance mutations in the herpes simplex virus thymidine kinase (UL23), DNA polymerase (UL30), helicase (UL5) and primase (UL52) genes using sequencing techniques.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess proficiency of laboratories in the detection of Legionella species.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the ability of laboratories molecular assays to detect different types and concentrations of parechovirus.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The Respiratory I EQA will focus on the molecular detection and determination of various influenza A & B and respiratory syncytial virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The Respiratory II EQA will focus on the molecular detection and determination of human metapneumovirus, respiratory adenoviruses, rhinoviruses , seasonal coronaviruses (e.g. NL63, OC43 etc), enterovirus and parainfluenza viruses. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

The Respiratory III EQA will focus on the molecular detection and determination of various Bordetella pertussis, Legionella pneumophila, Mycoplasma pneumoniae, Streptococcus pneumoniae or Haemophilus influenzae strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the ability of laboratories molecular assays to detect different concentrations of Varicella-Zoster virus (VZV).

To review the performance of laboratories quantitative VZV molecular assays.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the molecular detection of Mycobacterium tuberculosis complex.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories to detect atypical mycobacterium or non-tuberculous mycobacteria (NTM).

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Human Papillomavirus (HPV) infection has been detected in over 95% of cervical cancers. The second most common cancer detected in females worldwide. The detection of HPV infection is an important part of the triage, with cytomorphological examination in the early detection of cervical cancer in scrapings. For effective triage, quantitative detection and accurate HPV-typing at clinically relevant levels is essential. The introduction of nucleic acid amplification technologies (NAT) and nucleic acid hybridisation assays has led to the development of sensitive, type specific diagnostic tests that can rapidly identify HPV infection. As a result, these tests are now of great practical and clinical relevance. The aim of the EQA is to assess the proficiency of laboratories in the detection of different high risk Human Papillomavirus types within a PreservCyt matrix.

To assess the proficiency of laboratories in the detection of different high risk human papillomavirus (HPV) types within a PreservCyt^® matrix.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the proficiency of laboratories in the detection and quantitation of adenovirus.

To assess the proficiency of laboratories in the detection of different adenovirus serotypes including currently circulating serotypes of interest.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories molecular assays in detecting various types and concentrations of BK virus (BKV).

To assess the proficiency of laboratories in the reliable quantitation of BKV viral load.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection and quantitation of human cytomegalovirus (CMV).

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the laboratories’ ability to detect CMV drug resistance mutations in kinase UL97, polymerase UL54 gene and the UL56 that forms part of the terminase, using sequencing techniques.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Cytomegalovirus (CMV) is a betaherpes virus with a high prevalence (40-80%) in populations throughout the developed world. CMV is normally a latent lifelong infection that is completely asymptomatic in those infected with the virus. The situation in persons with compromised immune systems such as transplant recipients is much more serious, with CMV recognised as one of the most important viral pathogens causing high rates of mortality and morbidity in these groups. It is also a highly prevalent congenital infectious agent throughout the developed world. The clinical consequences of infection may be present at birth or manifest themselves during childhood. While blood samples are tested routinely and used for diagnosis and monitoring purposes, a range of other non-blood specimens are also extremely useful as they are non-invasive and usual have increased viral load, these samples include urine and salivary swab. The introduction of nucleic acid amplification technologies (NAT) has led to the development of sensitive diagnostic tests that can rapidly confirm or exclude CMV infection. As a result, these tests are now of great practical and clinical relevance.

The aim of the EQA scheme is to assess the performance of molecular based assays on non-blood specimen types, which includes urine, swab and amniotic fluid.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To evaluate the ability of laboratories in the detection of CMV from whole blood samples.

To assess the precision of molecular assays at clinically relevant viral loads.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the proficiency of laboratories in the detection and quantitation of Epstein-Barr virus (EBV).

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection and quantitation of Epstein-Barr virus (EBV) in whole blood samples.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories' molecular assays in the detection of various types of human herpes virus 6 (HHV6).

To assess the proficiency of laboratories in the reliable quantitation of HHV6 viral load.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories molecular assays in detecting various types and concentrations of JC virus (JCV).

To assess the proficiency of laboratories in the reliable quantitation of JCV viral load.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The aim of the Sexually Transmitted Infection (STI) EQA is to assess the laboratories' ability to detect a range of sexual transmitted infections known to cause disease using their routine molecular diagnostic platform and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of Mycoplasma genitalium, Mycoplasma hominis, Trichomonas vaginalis, Ureaplasma urealyticum and Gardnerella vaginalis.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The sexually transmitted infection II EQA will focus on the molecular detection and determination of various Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, and herpes simplex virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the qualitative detection of Toxoplasma gondii at different concentrations.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The aim of the Torque Teno Virus (TTV) EQA is to assess laboratories ability to detect TTV using routine molecular diagnostic platforms and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of Bordetella species.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

A terminology update in the Clostridium field has introduced a name change from Clostridium difficile to Clostridioides difficile. This has been adopted by the European Study Group for Clostridium difficile. Please note that QCMD will however continue to refer to this scheme and associated pathogens as Clostridium difficile at this time.

To assess the proficiency of laboratories in the molecular detection of Clostridium difficile.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The central nervous system I (viral meningitis and encephalitis) EQA scheme will focus on the molecular detection and determination of various enterovirus, parechovirus, herpes simplex virus 1/2, Varicella-Zoster virus and JC virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The central nervous system II (non-viral meningitis and encephalitis) EQA scheme will focus on the molecular detection and determination of various Listeria spp, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae , Escherichia coli K1, Cryptococcus spp. or Haemophilus influenzae strains. The panel is designed to represent various clinical scenarios.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the correct detection of Chlamydophila pneumoniae.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the laboratories ability in the molecular detection of Chlamydia psittaci.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of coronavirus.

To assess the proficiency of laboratories in the detection of different coronavirus genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Different species of pathogenic bacteria are known to cause gastroenteritis. The panel members of this EQA will resemble clinical samples and may include current clinically relevant strains of Salmonella, Shigella, Yersinia, E.coli 0157, C. difficile or Campylobacter species. The aim of the Bacterial Gastroenteritis EQA is to assess laboratories ability to detect a range of bacterial pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Parasites are a frequent cause of gastroenteritis and are a growing risk in this age of global travel. The panel members of this EQA will resemble clinical samples and may include current clinically relevant strains of Giardia, Cryptosporidium, Dientamoeba, Blastocystis and Entamoeba. The aim of the Parasitic Gastroenteritis EQA is to assess laboratories' ability to detect a range of parasitic pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Viruses are a major cause of gastroenteritis outbreaks. It has been estimated that at least 50% of foodborne gastroenteritis cases are caused by noroviruses. Approximately another 20% of cases, and the majority of severe cases in children, are due to rotavirus. Other clinically significant viral enteropathogens include adenovirus, particularly types 40 and 41, and astroviruses. The aim of the Viral Gastroenteritis EQA is to assess laboratories ability to detect a range of viral pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of norovirus, rotavirus, astrovirus, sapovirus and adenovirus.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in detection of influenza virus RNA.

To assess the proficiency of laboratories in distinguishing influenza virus A and B.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories molecular technologies for the detection and determination of MERS-CoV from other coronaviruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the correct detection of Mycoplasma pneumoniae.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the sensitivity and specificity of laboratories in the detection of human metapneumovirus (MPV).

To assess the ability of laboratories in the detection of different human MPV types.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the specificity and sensitivity of laboratories in the detection of norovirus.

To assess the ability of the laboratories to detect different norovirus genogroups.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the proficiency of laboratories in the detection of parainfluenza virus.

To assess the proficiency of laboratories in the detection of different parainfluenza virus types.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The Respiratory I Plus EQA will focus on the molecular detection and determination of various influenza A & B, respiratory syncytial virus strains and SARS-Cov-2. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the specificity and sensitivity of laboratories in the detection of respiratory syncytial virus (RSV) by NAT.

To assess the ability of laboratories in the detection of different RSV types by NAT.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of rhinovirus.

To assess the proficiency of laboratories in the detection of different rhinovirus genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of SARS-CoV-2 coronavirus.

To assess the proficiency of laboratories in the differentiation of different coronavirus genotypes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The viral transplant EQA scheme will focus on the molecular detection and determination of various cytomegalovirus, Epstein-Barr virus, human herpes virus 6, BK virus, B19 virus and adenovirus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of drug resistance mutations in the hepatitis B virus (HBV) DNA polymerase gene using sequencing techniques and/or LiPA technology.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The QCMD HCV Drug Resistance (HCVDR) scheme has to-date been based around resistance to the first generation Direct Acting Antiviral (DAA) NS3 protease inhibitors, boceprevir and telaprevir, which became widely available circa 2011. However the “previr” family of drugs are only effective against HCV genotype 1 infections limiting the scope of the HCVDR programme to single genotype, single gene target. First generation DAAs were supplemented in 2014 with the release of the first “buvir” NS5b inhibitors for use against genotype 1 followed by the release of the first NS5a inhibitor “asvir” family of drugs in 2015, which are effective against both genotype 1 and 3 infections. All three drug families are now in routine use and are included in both the WHO list of essential medicines and the national guidelines of several countries for treatment of HCV. Based on this the HCVDR programme has been updated to reflect the current clinical environment with regards to drug resistance testing.

The aim of the HCVDR EQA is to assess the performance of laboratories in the detection of drug resistance mutations in the hepatitis C virus (HCV) genotypes 1 and 3 (NS3 and NS5 regions) using sequencing techniques.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection and quantitation of human immunodeficiency virus type 2 (HIV-2).

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of Mycoplasma genitalium.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in detection of mumps using routine molecular methods.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Rash is a common symptom in patients, particularly children, with a range of different aetiologies both infectious and non-infectious. Identification and differentiation is important between infectious causes both for patient management and infection and public health control to ensure if appropriate outbreak management is appropriately handled.

The Rash Pilot EQA pilot study aims to evaluate the molecular detection and identification of infectious agents associated with skin rashes and eruptions. The panel will include clinically relevant viral and bacterial pathogens such as Measles virus, Rubella virus, Parvovirus B19, and Streptococcus pyogenes. Participating laboratories will be required to test each panel using their routine molecular diagnostic methods and submit individual results to QCMD for assessment.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of Trichomonas vaginalis.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the qualitative detection of Aspergillus species at different concentrations.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories to detect, identify and interpret which bacterial species are provided within each panel member using their routine 16S rRNA molecular diagnostic procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the qualitative detection of B. burgdorferi sensu lato genospecies complex at different concentrations.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Next generation sequencing (NGS) has been increasingly integrated in to routine diagnostics with several key areas of use being identified. One of these is the identification of bacterial pathogens and their associated resistance patterns which allows precise information for clinical decision making and infection control measures. The Bacterial NGS EQA pilot study aims to evaluate the ability of laboratories to sequence bacterial samples and report bacterial identification, relatedness and sites associated with drug resistance using next-generation sequencing (NGS) technologies. The panel will include clinically relevant bacterial isolates representing a range of species and genomic features. Participating laboratories will be required to process each panel using their validated NGS workflows and bioinformatics pipelines and submit individual results to QCMD for assessment.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Candida auris (C. auris) is an emerging fungal pathogen associated with nosocomial infections. It is considered a serious global health threat due to its multi-drug resistance and difficulty of identification using standard methods which can misidentify C. auris as other phenotypically related Candida species. C. auris spreads easily in healthcare settings where some patients can develop severe and even life-threatening symptoms especially in immunocompromised patients. Early and correct identification of patients colonised with C. auris is critical in containing its spread.

The pilot EQA scheme will assess laboratories ability in the molecular detection and identification of Candida auris .

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To evaluate the ability of laboratories to use molecular techniques for detection of Candida species.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess laboratories ability to detect dermatophytes using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess laboratories ability to detect diarrheagenic E. coli strains using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the laboratories ability to detect β-lactamase and carbapenemase coding genes in a clinical setting using their routine molecular diagnostic procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

Group A Streptococcus (GAS) is one of the most common causes of bacterial infections of the throat and skin. GAS or Streptococcus pyogenes is also the cause of ‘Scarlet fever’ which most commonly affects children between 5 and 15 years old. Early antibiotic treatment has been shown to be effective in reducing both the transmission and severity of disease therefore rapid diagnosis is key. The SARS-CoV-2 pandemic resulted in an influx of near patient / PoC molecular testing platforms, with GAS added to the test menu of several commercial instruments for use within a non-laboratory, point of impact test setting or in a ‘statim’ or ‘out of hours’ capacity within the central laboratory. We have therefore introduced a pilot EQA to assess the performance of molecular GAS testing, allowing test sites to assess the performance of their assays.

To assess the laboratories ability in the qualitative detection of group A Streptococcus species using their routine molecular diagnostic procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the laboratories’ ability in the qualitative detection of H. pylori .

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

Bone and Joint infection diagnosis can be challenging as the symptoms are similar to other common conditions such as gout and rheumatoid arthritis. Culturing can require up to two weeks due to the potentially fastidious nature of the pathogens associated with this type of infection. Average sensitivity rates of approximately 72% have been recorded and this can be further reduced where antibiotics have been administered. The aim of the joint infection pilot study is to assess the ability of laboratories to detect a range of Gram positive, Gram negative and fungal pathogens alongside common resistance markers using their routine molecular diagnostic platforms and procedures. The panel members will resemble clinical samples and will include current clinically relevant strains.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The primary aim of this EQA is to evaluate the ability of laboratories in the detection and determination of different clinically relevant isolates using MALDI-TOF and other similar mass spectrometry based technologies in the routine microbiology laboratory.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess laboratories ability in the molecular detection of Pneumocystis jirovecii .

To assess the sensitivity of molecular assays in routine clinical use for the detection of P. jirovecii.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

In 2022 the global outbreak of mpox began and continues to this day. This resulted in an increasing demand for laboratory preparedness, we have introduced a pilot EQA scheme for poxviruses that will include inactivated monkeypox virus and other orthopoxviruses (Cowpox, and Vaccinia). This offers laboratories, that have recently set up generic orthopoxvirus or specific monkeypox virus molecular diagnostics, the opportunity to assess the performance of their assays.

In 2022 the global outbreak of mpox began and continues to this day. This resulted in an increasing demand for laboratory preparedness, we have introduced a pilot EQA scheme for poxviruses that will include inactivated monkeypox virus and other orthopoxviruses (Cowpox, and Vaccinia). This offers laboratories, that have recently set up generic orthopoxvirus or specific monkeypox virus molecular diagnostics, the opportunity to assess the performance of their assays.

This EQA scheme consists of a range of pathogens associated with sepsis such as Staphylococcus spp., Escherichia coli, Enterococcus spp., Streptococcus spp., Klebsiella spp., Pseudomonas spp., and Candida spp. The participating laboratory will be required to use their current molecular diagnostic processes and procedures for the detection and identification of microorganisms associated with sepsis.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess laboratories ability to detect Treponema pallidum using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The Viral NGS EQA pilot study aims to evaluate the ability of laboratories to sequence viral samples and report viral identification using next-generation sequencing (NGS) technologies.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

This EQA will focus on the laboratories ability to detect and determine different VRE in clinically relevant sample types using molecular techniques.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Human Papillomavirus (HPV) infection has been detected in over 95% of cervical cancers, the second most common cancer detected in females worldwide. The detection of HPV infections is an important part of the triage with cytomorphological examination in the early detection of cervical cancer in scrapings. For effective triage, quantitative detection and accurate HPV-typing at clinically relevant levels is essential. The introduction of nucleic acid amplification technologies (NAT) and nucleic acid hybridisation assays has led to the development of sensitive, type specific diagnostic tests that can rapidly identify HPV infection. As a result, these tests are now of great practical and clinical relevance. To assess the proficiency of laboratories in the detection of different high risk Human Papillomavirus types within a SurePath™ matrix.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To determine laboratories ability to detect and differentiate Mycobacterium tuberculosis drug resistance strains using their routine molecular diagnostic procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

The Arthropod-borne virus EQA will focus on the molecular detection and determination of different arthropod-borne viruses (including viruses from Flavi-, Toga-, Bunya-, and/or Reoviridae families). The panel is designed to represent various clinical scenarios (fever, haemorrhagic symptoms and/or neurological illness) and may include medically important arboviruses such as tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, Rift Valley fever viruses, or Usutu virus. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Pathogens of the genus Babesia (Family: Babesiidae, Order: Piroplasmida) are blood parasites in mammals. Of the more than 100 known tick-borne species, only a few have been identified as causing human infections. Of zoonotic importance are parasites of bovine babesiosis (Babesia divergens and B. divergens-like forms) and rodent babesiosis (B. microti) During a blood meal, hard-bodied ticks inoculate sporozoites with their saliva, which, like plasmodia, enter human erythrocytes and undergo asexual reproduction. In Europe, B. divergens is the main pathogen of human babesiosis. Infections have been reported in various European countries. In the United States, B. microti is the agent most frequently identified. Other cases have been reported from Africa, Mexico, Japan, Taiwan and India (B. microti or unidentified Babesia). The diagnosis of an acute infection is confirmed through identification of Babesia on microscopic examination or detection of Babesia nucleic acid. Nucleic acid testing (NAT) correlates better correlates with active infection and more effectively identifies low-level infections than other laboratory tests, making them important for donor screening and donation testing to reduce the risk of transfusion-transmitted babesiosis.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection and identification of Babesia species causing human babesiosis.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Trypanosoma cruzi is a parasite and the causative agent of Chagas disease or American trypanosomiasis. T. cruzi is primarily transmitted by triatomine bugs. Parasite detection is difficult during both the acute and the latent phase of infection. Antibody detection plays a crucial role in laboratory diagnostics. Serological testing is also the method for blood donor screening. Compared to conventional techniques, molecular tools such as PCR offer improved sensitivity for detection of acute and early congenital disease and are considered the test of choice in these settings and can be useful for monitoring reactivation and parasitological response to treatment.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of Trypanosoma cruzi causing Chagas disease.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the laboratory’s ability to detect chikungunya virus using their routine molecular diagnostic platform and procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of dengue virus.

To assess the proficiency of laboratories in distinguishing dengue virus from other flaviviruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Tularemia is a severe zoonotic disease and is caused by the bacteria Francisella tularensis. Transmission is typically through the skin or mucous membranes. For example, infection can occur when improperly cooked meat (typically rabbit) is eaten or from contaminated water is drunk, inhalation or through arthropod bites. Reservoirs of Francisella tularensis include lagomorphs, rodents and blood-sucking arthropods. Laboratory confirmation of tularemia consists in detecting the bacteria in a biological sample or a specific antibody response. Molecular methods (i.e. PCR) are rapid and can allow identification of the subspecies and obviate the need for cultivation. Serological methods are routinely used for diagnosis and are considered highly specific despite cross-reactions with Brucella, Yersinia, Proteus, Legionella and Mycoplasma species may occur.

The pilot EQA scheme will assess the proficiency of laboratories on the detection of Francisella tularensis.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Malaria is a life threatening, mosquito borne, infectious disease in humans. The causative agents of malaria are a number of protozoan species of the genus Plasmodium. There are five Plasmodium species that commonly cause disease in humans. Plasmodium falciparum is the causative agent for most cases of malaria (malaria tropica) and is found across Africa. P. falciparum and malaria tropica are the most severe form and account for the majority of malaria fatalities worldwide. Plasmodium vivax (malaria tertiana) is the second most prevalent species and is found mostly in Latin America and Asia, whereas Plasmodium ovale sensu lato, which is also a causative agent of malaria tertiana, is mainly restricted to West African regions. Plasmodium malariae (malaria quartan) is found worldwide but at a relatively low incidence. Plasmodium knowlesi was identified as the causative agent of localised outbreaks in Malaysia and has since been reported in nearly all Southeast Asian countries. In Europe, malaria is mainly a travel medicine issue. In patients with a fever of unknown cause and a stay in an area where malaria is endemic, acute malaria must be excluded. The diagnosis of malaria is based on microscopic, serological or molecular detection of Plasmodium species. Although microscopy is still the most routinely used method for diagnosis by clinical laboratories, molecular testing has become increasingly popular.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of Plasmodium species.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of Methicillin Resistant Staphylococcus aureus.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the molecular typing for outbreak analysis of Methicillin Resistant Staphylococcus aureus .

This EQA scheme is suitable for all molecular methods for typing Staphylococcus aureus strains including SPA typing and whole genome sequence analysis, where the type and/or the relationship between isolates can be determined.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of West Nile virus.

To determine the proficiency of laboratories in distinguishing West Nile virus from other flaviviruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of yellow fever virus.

To determine the proficiency of laboratories in distinguishing yellow fever virus from other flaviviruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity

To assess the proficiency of laboratories in the detection of Zika virus and determine the proficiency of laboratories in distinguishing Zika virus from other flaviviruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

Dried blood spot testing for blood borne virus diagnosis is typically used to support screening in settings where plasma or serum sampling and cold storage is challenging.

The pilot EQA scheme will assess the performance of laboratories in the detection of hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) from dried blood spots.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of clinically relevant levels of human cytomegalovirus (CMV) from dried blood spots.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To evaluate laboratories in the detection of HDV within the routine clinical setting.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To evaluate the ability of laboratories in the detection and quantification of hepatitis E virus (HEV).

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the performance of laboratories in the detection of drug resistance mutations in the HIV-1 protease, reverse transcriptase, and integrase genes.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the laboratories ability in the qualitative detection of group B Streptococcus using their routine molecular diagnostic procedures.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.

To assess the proficiency of laboratories in the detection of different influenza virus types, subtypes and lineages.

To assess the proficiency of laboratories in the typing and subtyping/lineage determination of influenza viruses.

The panels have been evaluated by laboratories using various commercial and in-house methodologies. Full instructions for the processing and preparation of the samples is provided with the panel. The QCMD electronic results submission system ensures full participant confidentiality and anonymity throughout the programme. Participants will receive a report and a certificate of participation for the EQA programme. Participation in this EQA programme is limited. To ensure inclusion in the scheme please register at the earliest opportunity.